Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10918460 | Radiotherapy and Oncology | 2014 | 7 Pages |
Abstract
A rapid learning environment is possible with the quality of clinical data sufficient to validate a DSS. It uses patient and tumor features to identify prognostic groups in whom therapy can be individualized based on predicted outcomes. Especially the survival benefit of a radical versus non-radical dose predicted by the DSS for various prognostic groups has clinical relevance, but needs to be prospectively validated.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Andre Dekker, Shalini Vinod, Lois Holloway, Cary Oberije, Armia George, Gary Goozee, Geoff P. Delaney, Philippe Lambin, David Thwaites,